Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial
Titel:
Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial
Auteur:
Breder, Ikaro Wolf, Vaneza Lira W. Soares, Alexandre A.S. de Carvalho, Luiz Sergio F. Kimura-Medorima, Sheila T. Cintra, Riobaldo M. Barreto, Joaquim Munhoz, Daniel B. Cunha, Jessica S. Bonilha, Isabella Coelho-Filho, Otavio R. Quinaglia, Thiago Nadruz, Wilson Guerra-Junior, Gil Muscelli, Elza Sposito, Andrei C.